"Epoetin Alfa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.
| Descriptor ID |
D000068817
|
| MeSH Number(s) |
D12.644.276.374.410.240.150.500 D12.776.395.240.150.750 D12.776.467.374.410.240.150.500 D23.529.374.410.240.150.750
|
| Concept/Terms |
Epoetin Alfa- Epoetin Alfa
- Alfa, Epoetin
- Recombinant 1-165 Erythropoietin, Glycoform Alpha
- Recombinant 1 165 Erythropoietin, Glycoform Alpha
|
Below are MeSH descriptors whose meaning is more general than "Epoetin Alfa".
Below are MeSH descriptors whose meaning is more specific than "Epoetin Alfa".
This graph shows the total number of publications written about "Epoetin Alfa" by people in this website by year, and whether "Epoetin Alfa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epoetin Alfa" by people in Profiles.
-
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol. 2016 Oct; 27(10):3129-3138.
-
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
-
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
-
Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2014 Mar 31; (3):CD009297.
-
Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
-
Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit Care Med. 2009 Apr; 37(4):1299-307.
-
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7.
-
Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004 Oct; 66(4):1712; author reply 1712-3.
-
Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. J Investig Med. 2001 Jul; 49(4):335-45.